ADCT-602

ADCT-602 is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that specifically binds to CD22, a cell surface antigen highly expressed on most malignant B-cells. The antibody is site-specifically conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin via a biodegradable linker. Upon binding to CD22-expressing cells, ADCT-602 is internalized and the PBD-based cytotoxic payload is released inside the cell, leading to DNA interstrand crosslink formation and subsequent cell death. This mechanism enables targeted killing of malignant B-cells while sparing non-target cells. ADCT-602 has demonstrated potent anti-tumor activity in preclinical models and is being evaluated in clinical trials for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It was also under development for non-Hodgkin lymphoma such as diffuse large B-cell lymphoma[1][3][4][5][6].